ARCT vs. CNXC

Last updated Jun 4, 2026

ARCT (Arcturus Therapeutics Holdings Inc.) and CNXC (Concentrix Corporation) are both stocks. ARCT operates in Biotechnology (Healthcare), while CNXC operates in Information Technology Services (Technology). Over the past 5 years, ARCT returned -24.38%/yr vs -27.24%/yr for CNXC. At a 0.25 correlation, their price movements are largely independent.

Performance

ARCT vs. CNXC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARCT achieves a 23.98% return, which is significantly higher than CNXC's -31.89% return.

ARCT

• 1D: -0.65%
• 1M: -11.32%
• YTD: 23.98%
• 6M: 15.33%
• 1Y: -41.54%
• 3Y*: -34.37%
• 5Y*: -24.38%
• 10Y*: —

CNXC

• 1D: -2.84%
• 1M: 17.74%
• YTD: -31.89%
• 6M: -23.31%
• 1Y: -47.71%
• 3Y*: -30.68%
• 5Y*: -27.24%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARCT vs. CNXC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ARCT Arcturus Therapeutics Holdings Inc.	23.98%	-63.88%	-46.18%	85.91%	-54.17%	-14.68%	-27.87%
CNXC Concentrix Corporation	-31.89%	-1.39%	-55.03%	-25.36%	-24.91%	81.22%	23.37%

Correlation

The correlation between ARCT and CNXC is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.25
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (All Time) Calculated using the full available price history since Nov 25, 2020	0.25

Fundamentals

Market Cap ARCT : $216.00M CNXC : $1.70B
EPS ARCT : -$1.81 CNXC : -$21.33
PS Ratio ARCT : 4.47 CNXC : 0.17
PB Ratio ARCT : 1.13 CNXC : 0.61
Total Revenue (TTM) ARCT : $46.80M CNXC : $9.95B
Gross Profit (TTM) ARCT : $40.72M CNXC : $3.27B
EBITDA (TTM) ARCT : -$84.61M CNXC : -$944.68M

Return for Risk

ARCT vs. CNXC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT

ARCT Risk / Return Rank: 25
ARCT Sharpe Ratio Rank: 21
ARCT Sortino Ratio Rank: 28
ARCT Omega Ratio Rank: 28
ARCT Calmar Ratio Rank: 21
ARCT Martin Ratio Rank: 26

CNXC

CNXC Risk / Return Rank: 11
CNXC Sharpe Ratio Rank: 9
CNXC Sortino Ratio Rank: 12
CNXC Omega Ratio Rank: 12
CNXC Calmar Ratio Rank: 11
CNXC Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARCT vs. CNXC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARCT	CNXC	Difference
Sharpe ratio Return per unit of total volatility	-0.45	-0.78	+0.33
Sortino ratio Return per unit of downside risk	-0.08	-0.93	+0.84
Omega ratio Gain probability vs. loss probability	0.99	0.88	+0.11
Calmar ratio Return relative to maximum drawdown	-0.56	-0.78	+0.22
Martin ratio Return relative to average drawdown	-0.79	-1.30	+0.51
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARCT vs. CNXC - Sharpe Ratio Comparison

The current ARCT Sharpe Ratio is -0.45, which is higher than the CNXC Sharpe Ratio of -0.78. The chart below compares the historical Sharpe Ratios of ARCT and CNXC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ARCT	CNXC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.45	-0.78	+0.33
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.27	-0.57	+0.30
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.33	+0.20

Drawdowns

ARCT vs. CNXC - Drawdown Comparison

The maximum ARCT drawdown since its inception was -95.23%, which is greater than CNXC's maximum drawdown of -87.86%. Use the drawdown chart below to compare losses from any high point for ARCT and CNXC.

Drawdown Indicators

	ARCT	CNXC	Difference
Max Drawdown Largest peak-to-trough decline	-95.23%	-87.86%	-7.37%
Max Drawdown (1Y) Largest decline over 1 year	-74.53%	-61.71%	-12.82%
Max Drawdown (3Y) Largest decline over 3 years	-86.71%	-76.50%	-10.21%
Max Drawdown (5Y) Largest decline over 5 years	-89.87%	-87.86%	-2.01%
Current Drawdown Current decline from peak	-93.85%	-85.33%	-8.52%
Average Drawdown Average peak-to-trough decline	-72.98%	-47.57%	-25.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	52.77%	36.86%	+15.91%

Volatility

ARCT vs. CNXC - Volatility Comparison

Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 18.67% compared to Concentrix Corporation (CNXC) at 15.88%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARCT	CNXC	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.67%	15.88%	+2.79%
Volatility (6M) Calculated over the trailing 6-month period	40.13%	51.82%	-11.69%
Volatility (1Y) Calculated over the trailing 1-year period	92.40%	61.20%	+31.20%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.77%	48.24%	+43.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	102.22%	49.79%	+52.43%

Dividends

ARCT vs. CNXC - Dividend Comparison

ARCT has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 5.10%.

Position	TTM	2025	2024	2023	2022	2021
ARCT Arcturus Therapeutics Holdings Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
CNXC Concentrix Corporation	5.10%	3.27%	2.87%	1.15%	0.77%	0.14%

Financials

Frequently Asked Questions

Can I hold both ARCT and CNXC in my portfolio?

ARCT and CNXC have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARCT or CNXC?

ARCT has higher volatility (18.67%) compared to CNXC (15.88%). In terms of maximum drawdown, ARCT dropped -95.23% vs CNXC's -87.86%.

Which has better risk-adjusted returns?

ARCT currently has the higher Sharpe Ratio (-0.45 vs -0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.